| 25.59 0.02 (0.08%) | 06-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.91 | 1-year : | 34.93 |
| Resists | First : | 25.61 | Second : | 29.91 |
| Pivot price | 25.53 |
|||
| Supports | First : | 25.44 | Second : | 25.34 |
| MAs | MA(5) : | 25.57 |
MA(20) : | 25.51 |
| MA(100) : | 18.45 |
MA(250) : | 0 | |
| MACD | MACD : | 0.9 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 85 |
| RSI | RSI(14): 85.5 | |||
| 52-week | High : | 25.61 | Low : | 9.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DCPH ] has closed below upper band by 15.4%. Bollinger Bands are 96.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 25.62 - 25.75 | 25.75 - 25.87 |
| Low: | 25.26 - 25.42 | 25.42 - 25.55 |
| Close: | 25.33 - 25.6 | 25.6 - 25.82 |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Thu, 25 Jul 2024
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Acquired by Swiss National Bank - Defense World
Mon, 22 Jul 2024
BNP Paribas Financial Markets Sells 41,173 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) - Defense World
Fri, 10 May 2024
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Tue, 30 Apr 2024
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals - PR Newswire
Tue, 30 Apr 2024
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 86 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 28.4 (%) |
| Held by Institutions | 72 (%) |
| Shares Short | 3,920 (K) |
| Shares Short P.Month | 5,750 (K) |
| EPS | -2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.84 |
| Profit Margin | -108.9 % |
| Operating Margin | -108.6 % |
| Return on Assets (ttm) | -26.7 % |
| Return on Equity (ttm) | -50.4 % |
| Qtrly Rev. Growth | 34.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.02 |
| EBITDA (p.s.) | -2.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -152 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -11.58 |
| PEG Ratio | -0.7 |
| Price to Book value | 6.64 |
| Price to Sales | 12.65 |
| Price to Cash Flow | -14.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|